Common antibiotic linked to higher risk of death in adults, major study finds

Global Study Links Cefepime to Higher 30‑Day Mortality, Urges Careful Dosing

A pooled analysis of 110 randomized trials involving more than 22,000 patients found that the broad‑spectrum antibiotic cefepime was associated with a higher risk of death within 30 days of treatment compared with other beta‑lactam antibiotics. The research, published in JAMA Network Open late last month, raised concerns about the drug’s safety profile in hospitalized patients who receive it for serious bacterial infections.

Cefepime, an injectable cephalosporin, is a staple in hospitals worldwide for treating conditions such as pneumonia, urinary tract infections, skin and soft‑tissue infections, meningitis, and the life‑threatening complication of febrile neutropenia—a fever that accompanies dangerously low white‑blood‑cell counts in patients undergoing chemotherapy or with other immunocompromising illnesses.

Key Findings

• 778 deaths were recorded among 11,726 patients who received cefepime, a 6.6 % mortality rate.
• In contrast, patients given other beta‑lactam antibiotics had a 6.2 % mortality rate.
• A Bayesian meta‑analysis estimated a 94.4 % probability that cefepime was linked to higher all‑cause mortality.
• When the analysis was restricted to 73 peer‑reviewed trials, the probability rose to 98.6 %.
• The association was strongest in adult patients and particularly pronounced in those treated for febrile neutropenia.

The study did not establish a direct causal relationship but highlighted a statistically significant association. Researchers emphasized that the observed differences could stem from factors such as inadequate drug levels, neurotoxicity when doses are too high, or the inherent severity of the conditions being treated.

Possible Explanations

“Both under‑dosing and over‑dosing can contribute to poorer outcomes,” said Dr. Marc Siegel, a senior medical analyst at Fox News who was not involved in the research. “The drug itself may not be the culprit; it’s the challenge of finding the right dose.” Siegel added that artificial intelligence could help clinicians determine optimal dosing and monitor patient responses.

Study Limitations

The analysis combined trials that varied widely in design, patient populations, dosing regimens, and comparator antibiotics—some dating back several decades. Such heterogeneity can complicate interpretation. Moreover, the study identified an association, not proof that cefepime causes increased mortality.

Clinical Implications

The authors of the study do not recommend stopping use of cefepime outright. Instead, they call for updated dosing guidelines and further research to clarify safety, especially for vulnerable groups like elderly patients or those with renal impairment who may be at higher risk of neurotoxic side effects such as confusion, decreased consciousness, and seizures.

Moving Forward

Hospitals and clinicians will need to weigh the benefits of cefepime’s broad antimicrobial coverage against the potential risks highlighted by this global review. Ongoing surveillance, careful dose adjustment, and targeted research into patient subgroups may help mitigate the higher mortality signal identified in this comprehensive analysis.